Brokerages Set United Therapeutics Co. (NASDAQ:UTHR) PT at $370.86

United Therapeutics Co. (NASDAQ:UTHR) has earned a consensus recommendation of “Moderate Buy” from the fifteen analysts that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and twelve have assigned a buy rating to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $370.86.

A number of analysts have recently issued reports on UTHR shares. StockNews.com raised shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 17th. The Goldman Sachs Group boosted their price objective on shares of United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research report on Friday, November 1st. HC Wainwright upped their price objective on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. LADENBURG THALM/SH SH upped their price objective on shares of United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a report on Thursday, October 31st. Finally, Argus upped their price objective on United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st.

Insider Activity

In other news, Director Nilda Mesa sold 224 shares of the firm’s stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $412.28, for a total value of $92,350.72. Following the transaction, the director now directly owns 5,783 shares in the company, valued at approximately $2,384,215.24. This trade represents a 3.73 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO Michael Benkowitz sold 14,700 shares of United Therapeutics stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $374.46, for a total transaction of $5,504,562.00. Following the completion of the sale, the chief operating officer now owns 2,577 shares in the company, valued at approximately $964,983.42. This represents a 85.08 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 113,396 shares of company stock worth $42,175,418. 11.90% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. LSV Asset Management increased its holdings in United Therapeutics by 82.5% in the 2nd quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company’s stock valued at $307,837,000 after buying an additional 436,851 shares during the period. Swedbank AB acquired a new position in United Therapeutics during the 1st quarter worth about $97,316,000. FMR LLC lifted its position in United Therapeutics by 41.1% during the 3rd quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company’s stock worth $386,168,000 after buying an additional 314,004 shares in the last quarter. Canada Pension Plan Investment Board lifted its position in United Therapeutics by 567.2% during the 1st quarter. Canada Pension Plan Investment Board now owns 180,800 shares of the biotechnology company’s stock worth $41,533,000 after buying an additional 153,700 shares in the last quarter. Finally, Assetmark Inc. lifted its position in United Therapeutics by 56.9% during the 3rd quarter. Assetmark Inc. now owns 419,957 shares of the biotechnology company’s stock worth $150,492,000 after buying an additional 152,249 shares in the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Trading Down 3.5 %

Shares of UTHR opened at $386.27 on Friday. The stock has a 50-day moving average price of $362.57 and a 200-day moving average price of $326.65. The company has a market cap of $17.25 billion, a PE ratio of 16.96, a price-to-earnings-growth ratio of 1.17 and a beta of 0.56. United Therapeutics has a 12-month low of $208.62 and a 12-month high of $417.82.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, beating the consensus estimate of $6.16 by $0.23. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The business had revenue of $748.90 million during the quarter, compared to analysts’ expectations of $722.62 million. During the same quarter in the prior year, the company posted $5.38 EPS. The firm’s revenue for the quarter was up 22.9% compared to the same quarter last year. As a group, analysts predict that United Therapeutics will post 25.1 earnings per share for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.